Erratum to : Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres, Vicente E; Chapman, Arlene B; Devuyst, Olivier; Gansevoort, Ron T; Perrone, Ronald D; Dandurand, Ann; Ouyang, John; Czerwiec, Frank S; Blais, Jaime D; TEMPO 4:4 Trial Investigators

doi:10.1093/ndt/gfx079

Erratum to : Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.

Torres, Vicente E

;

Chapman, Arlene B

;

Devuyst, Olivier

;

Gansevoort, Ron T

;

TEMPO 4:4 Trial Investigators

;et.al.

(2017) Nephrology, Dialysis, Transplantation — Vol. 32, n° 7, p. 1262 (2017)

Files

2017_Torres_Nephrol_Dial_Transplant_Erratum.pdf

Restricted Access
Adobe PDF
81.11 KB

Request a copy

Details

Authors

Torres, Vicente E
Author
Chapman, Arlene B
Author
Devuyst, OlivierUCLouvain
Author
Gansevoort, Ron T
Author
TEMPO 4:4 Trial Investigators
Author

Affiliations

Citations

APA
Chicago
FWB

Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Perrone, R. D., Dandurand, A., Ouyang, J., Czerwiec, F. S., Blais, J. D., & TEMPO 4:4 Trial Investigators. (2017). Erratum to : Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial. Nephrology, Dialysis, Transplantation, 32(7), 1262. https://doi.org/10.1093/ndt/gfx079 (Original work published 2017)